Healio

Cell-free DNA blood test ‘poised to have significant impact’ on CRC screening

Please provide your email address to receive an email when new articles are posted on . “The cell-free DNA is the first blood-based test with performance that is comparable to current guideline ...
Healio

Blood-based CRC screening test identifies asymptomatic, low-grade tumors

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — Multimodal circulating tumor DNA blood-based colorectal cancer screening tests may have clinically ...
Nasdaq

Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People

MADISON, Wis., April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most ...
MedPage Today

Blood Test for CRC Screening Lags Behind Other Options in Cost-Effectiveness Study

New blood-based screening tests for colorectal cancer (CRC) offered fewer benefits at higher cost versus other screening options, a cost-effectiveness modeling study suggested. In a comparison against ...
Medscape

FDA OKs Next-Gen Cologuard Test for CRC Screening

The US Food and Drug Administration (FDA) approved Exact Sciences' next-generation multitarget stool DNA (mt-sDNA) test, Cologuard Plus, for use in adults 45 or older who are at average risk for ...
Becker's ASC

Next-generation CRC test earns FDA approval

The FDA has approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer. The FDA’s approval was based on findings ...
Becker's ASC

Beating CRC, one test at a time — Exact Sciences’ Mark Stenhouse stumps for Cologuard

Mark Stenhouse left his executive role at AbbVie to join Exact Sciences because he felt the company was fighting a worthy battle: preventing colorectal cancer. Mr. Stenhouse, now Exact Science’s ...
Business Wire

PREEMPT CRC™ Trial for Blood-Based Test to Detect Colon Cancer Has Expanded to Enroll Patients From Anywhere in the Continental U.S. During COVID-19 Pandemic

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...
Morningstar

Freenome Delivers Improved Performance in Its Colorectal Cancer Blood Test with Sensitivity of 85% for CRC and 22% for Advanced Precancerous Lesions

– As presented later this week at the ASCO GI conference, the large case-control validation study of nearly 1,000 samples highlights a head-to-head comparison with the test's first version, which is ...
Medscape

Stages I-III Screen-Detected CRC Boosts Disease-Free Survival Rates

Patients with stages I-III screen-detected colorectal cancer (CRC) have better disease-free survival rates than those with non-screen–detected CRC, an effect that was independent of patient, tumor, ...
ascopubs.org

Quantification of circulating tumor DNA (ctDNA) using a methylation-based, tissue-free colorectal cancer (CRC) test for the detection of molecular residual disease (MRD).

Assessing adjuvant chemotherapy benefit in younger and older molecular residual disease–positive patients with stage II/III colorectal cancer. This is an ASCO Meeting Abstract from the 2026 ASCO ...